TG Therapeutics (TGTX) is up 11.9% today. Here is some analysis on what might have caused this price movement.
Analysis: The move appears tied less to a single fresh headline and more to renewed buying after investors digested TG Therapeutics’ recent quarterly update. The company raised its 2026 revenue outlook for BRIUMVI, highlighted encouraging progress in its simplified dosing program, and continues to point to a potential late-2026 or early-2027 catalyst from subcutaneous BRIUMVI.
Details:
In its second-quarter 2026 update, TG Therapeutics raised full-year revenue guidance and increased its BRIUMVI U.S. net product revenue target, reinforcing confidence in the drug’s commercial trajectory.The company said the ENHANCE study met its primary endpoint, supporting a possible one-day infusion approach that could make treatment more convenient if regulators ultimately agree.TG Therapeutics has also said its Phase 3 trial for subcutaneous BRIUMVI is fully enrolled, with top-line data expected around year-end 2026 or early 2027, giving investors another visible pipeline milestone.This could also be because the stock had been consolidating after earnings, and today’s gain looks consistent with a rebound as the market refocuses on sales momentum and future label-expansion opportunities.Sources:
TG Therapeutics, SEC, Investing.com
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
Quiver Alerts
Receive TGTX Data Alerts
Get market-moving data, filings, and signals for TGTX in real time.
Sign Up
$TGTX Hedge Fund Activity
We have seen 251 institutional investors add shares of $TGTX stock to their portfolio, and 182 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 2,700,463 shares (+385.6%) to their portfolio in Q2 2026, for an estimated $148,363,437
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,134,922 shares (+337.4%) to their portfolio in Q2 2026, for an estimated $117,292,614
- CITADEL ADVISORS LLC removed 1,385,719 shares (-72.1%) from their portfolio in Q2 2026, for an estimated $76,131,401
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,313,103 shares (+inf%) to their portfolio in Q2 2026, for an estimated $72,141,878
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,101,424 shares (-27.3%) from their portfolio in Q2 2026, for an estimated $60,512,234
- TWO SIGMA INVESTMENTS, LP added 926,659 shares (+60.1%) to their portfolio in Q2 2026, for an estimated $50,910,645
- STATE STREET CORP removed 863,295 shares (-10.0%) from their portfolio in Q2 2026, for an estimated $47,429,427
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TGTX Price Targets
Multiple analysts have issued price targets for $TGTX recently. We have seen 2 analysts offer price targets for $TGTX in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Alec Stranahan from B of A Securities set a target price of $20.0 on 07/07/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $70.0 on 07/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
TG Therapeutics Stock Jumps as Investors Reassess Growth Outlook
TG Therapeutics (TGTX) is up 11.9% today. Here is some analysis on what might have caused this price movement.
Analysis: The move appears tied less to a single fresh headline and more to renewed buying after investors digested TG Therapeutics’ recent quarterly update. The company raised its 2026 revenue outlook for BRIUMVI, highlighted encouraging progress in its simplified dosing program, and continues to point to a potential late-2026 or early-2027 catalyst from subcutaneous BRIUMVI.
Details:
Sources:
TG Therapeutics, SEC, Investing.com
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$TGTX Hedge Fund Activity
We have seen 251 institutional investors add shares of $TGTX stock to their portfolio, and 182 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TGTX Price Targets
Multiple analysts have issued price targets for $TGTX recently. We have seen 2 analysts offer price targets for $TGTX in the last 6 months, with a median target of $45.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »